We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Rival Biologics Bills May Determine No. Of Patent Suits

Law360 (March 20, 2009, 12:00 AM EDT) -- Competing bills have come out seeking to create a regulatory pathway for the U.S. Food and Drug Administration to approve follow-on versions of biologic drugs – with key differences that will likely spur or decrease patent litigation, experts say.

A bill introduced by Rep. Henry Waxman, D-Calif., would stick close to the existing regulatory scheme for approving generic pharmaceutical drugs and give incentives to follow-on companies to challenge patents held by innovator firms, while a rival measure proposed by Rep. Anna G. Eshoo, D-Calif., would lengthen...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.